Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 29,400 shares, a decrease of 41.2% from the June 30th total of 50,000 shares. Based on an average daily trading volume, of 50,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.7% of the shares of the company are short sold.
Tharimmune Price Performance
Shares of NASDAQ THAR traded up $0.15 during midday trading on Friday, hitting $3.23. 19,274 shares of the stock traded hands, compared to its average volume of 41,150. The firm has a 50-day moving average of $3.92 and a two-hundred day moving average of $5.32. Tharimmune has a one year low of $2.75 and a one year high of $142.50.
Tharimmune (NASDAQ:THAR – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($2.85) earnings per share for the quarter.
Tharimmune Company Profile
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Articles
- Five stocks we like better than Tharimmune
- Technology Stocks Explained: Here’s What to Know About Tech
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Calculate Options Profits
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How is Compound Interest Calculated?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.